Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Highest usefulness score first. Studies without a score come last.
-
We performed a retrospective analysis of the patients assessed at our memory unit for whom Alzheimer disease (AD) cerebrospinal fluid biomarker results were available.
Why it matters
In this retrospective analysis of 110 patients with mild cognitive impairment due to Alzheimer's disease, higher baseline total and phosphorylated tau levels were found in those who progressed to dementia. This is prognostic information only and does not report any treatment, cure, or prevention.
-
Neuropsychological assessments are essential to define the cognitive profile and contribute to the diagnosis of Alzheimer's disease (AD).
Why it matters
This study explored how performance on the NEURONORMA cognitive battery relates to cerebrospinal fluid amyloid and tau biomarkers across cognitively unimpaired, mild cognitive impairment and mild Alzheimer's dementia groups. It is about linking cognition to biomarkers, not about treating, curing or preventing the disease.
-
Høilund-Carlsen and colleagues raise concern regarding the reliability of amyloid PET to exclude Alzheimer disease.
Why it matters
This reply discusses the diagnostic challenges in Alzheimer disease and the limitations of amyloid in diagnosis and in evaluating therapy response. It presents additional studies of amyloid PET but reports no treatment or cure.
-
A Cognitive Task Force (CTF) was established for the MissionAD program with the aim of reducing the screen failure (SF) rate to ∼30% and thereby reduce unnecessary subject burden, site burden, and excess trial costs.
Why it matters
This report describes a Cognitive Task Force set up to improve cognitive screening efficiency in two global phase 3 studies of the BACE inhibitor elenbecestat in early Alzheimer's disease. The task force significantly improved screening efficiency, with a 24% decline in cognitive screen failure rate at the sites it supported.
-
32/100
The PORs of AD in rural counties in NTR increased by 18.3%, 4.7%, and 19% compared with urban counties for 2013, 2014, and 2015, respectively.
Why it matters
This study found higher prevalence of Alzheimer's disease in rural counties and across the Northeast Tennessee region compared with urban counties and other regions of Tennessee, and identified barriers to early screening and diagnosis such as denial, lack of patient awareness, inefficient screening methods, and lack of community resources. The authors call for prioritizing access to early screening in deprived areas, but this is about detection and resources, not treating, curing, or preventing the disease.
-
Dementia arising in patients with Parkinson disease or parkinsonian neurodegeneration comprises a heterogeneous neuropathology.
Why it matters
This review of PET amyloid imaging studies suggests that people with Parkinson disease have a lower incidence of amyloid deposition than elderly normal subjects, and that those with Parkinson disease with dementia also have a lower incidence. The reviewed reports often included only small-to-modest numbers of subjects.
-
Clinical indications of amyloid imaging in atypical dementia remain unclear.
Why it matters
In one 68-year-old woman with a complex corticobasal syndrome presentation, amyloid PET showed significant fibrillar amyloid deposition and led to a diagnosis of corticobasal syndrome with underlying Alzheimer pathology, after which a cholinesterase inhibitor was started. This is a single case report about diagnosis and does not establish any treatment, cure or prevention.
-
This influential review article proposed that Alzheimer's disease could be considered a brain-specific form of diabetes, arguing that impaired insulin and insulin-like growth factor signaling in the brain drives amyloid buildup, tau tangles, oxidative stress, and energy failure - the hallmark features of Alzheimer's - and coined the term 'type 3 diabetes' for this concept.
Why it matters
This review proposed that impaired brain insulin and IGF-1 signaling drives the hallmark features of Alzheimer's and coined the term 'type 3 diabetes' for the concept. It is a hypothesis-generating review, not a clinical trial, so it does not show that treating insulin resistance prevents or cures Alzheimer's.
-
The internal consistency (Cronbach's alpha) of the ADAS-cog were 0.91, 0.88 and 0.65 for the whole group, the AD and normal (i.e. non-demented) subjects respectively.
Why it matters
This study tested a Chinese version of a cognitive assessment scale in 39 elderly people in Hong Kong and found it reliable and valid for measuring thinking problems in Alzheimer's disease. It is a small study about a measurement tool, not about treating, curing or preventing the disease.
-
Immunocytochemical techniques was used to compare the proportion of neurons expressing various neurotransmitters (tyrosine hydroxylase, choline acetyltransferase and gamma-aminobutyric acid), neuropeptides (Leu-enkephalin and substance P) and neural cell adhesion molecules (NCAM) in the hippocampus, frontal (area 10) and occipital (area 17) cortices of neurologically normal elderly humans to that of age-matched Alzheimer disease (AD) patients.
Why it matters
Comparing brain tissue from normal elderly people and Alzheimer's patients, this study found no difference in GABAergic and cholinergic cells, but a significant decrease in catecholaminergic cells and NCAM-positive neurons in the frontal cortex of Alzheimer's patients. This is a tissue comparison describing brain changes, not a test of any treatment, cure or prevention.
-
Previous studies have shown a marked decline in neuronal and an increase in glial gene expression in Alzheimer's disease (AD) neocortex.
Why it matters
This study found declines in neuronal gene transcripts and increases in GFAP transcript in Alzheimer's brain tissue, with some changes related to age and pathology severity. It is an observational gene expression study and does not test any treatment or prevention for Alzheimer's disease.
-
A German family with 21 members affected by Alzheimer disease (AD) was studied clinically and genetically.
Why it matters
This family's dementia looked the same as the common sporadic form of Alzheimer's disease, but the pattern of inheritance was most consistent with autosomal-dominant transmission. It supports the idea that some Alzheimer's disease runs in families, but it does not test any treatment, cure, or prevention.
-
Women have twice the dementia risk compared with men.
Why it matters
This study looked at whether body fatness is linked to a higher Alzheimer's-related blood marker, p-tau217, in midlife women living in the community. The available text reports only that women have twice the dementia risk of men and does not state any result about the link between adiposity and p-tau217.
-
Effect size analysis proves the fact that the hybrid model produces statistically significant performance, as well as cases of clinically meaningful improvements over lightweight CNN baselines.
Why it matters
This hybrid quantum machine learning framework showed statistically significant performance and clinically meaningful improvements over lightweight CNN baselines for Alzheimer's classification. It is a diagnostic approach and does not report any treatment, cure, or prevention.
-
Alzheimer’s disease (AD) is characterized by progressive accumulation of amyloid-β (Aβ) peptides, initiating a pathological cascade from soluble monomers to toxic oligomers, protofibrils, fibrils, and ultimately extracellular amyloid plaques that contribute to synaptic dysfunction and neuronal degeneration.
Why it matters
Regulatory approvals of aducanumab, lecanemab and donanemab show significant plaque reduction and modest slowing of cognitive decline in early Alzheimer disease, supporting the amyloid hypothesis. Multiple clinical failures highlight limitations including late-stage intervention, inadequate targeting of neurotoxic oligomers, and safety concerns such as ARIA.
-
5/15 Patient:innen zeigten initial einen visuell negativen Tau-PET Scan zur Baseline, davon konvertierten vier im Follow-up zu einem Tau-positiven Befund.
Why it matters
This study used dynamic tau PET imaging to track tau buildup over time in 15 patients, finding that two quantitative measures reliably captured longitudinal increases in tau load. It is a small imaging study and does not test any treatment, cure, or prevention.
-
Theranostics—the use of diagnostic and therapeutic drugs that target the same molecular marker of disease—extends beyond the paradigm of radiopharmaceutical drug pairs used in oncologic settings (e.g., somatostatin receptor subtype 2 and prostate-specific membrane antigen theranostics) to other
Why it matters
This paper discusses theranostics, the use of diagnostic and therapeutic drugs targeting the same molecular marker, and FDA approval of amyloid PET drugs for selecting patients for amyloid-directed therapies. It is a labeling and regulatory update rather than a study of a new treatment or cure.
-
A Doença de Alzheimer (DA) é a principal causa de demência no mundo, caracterizada por processos neurodegenerativos progressivos que comprometem cognição, comportamento e funcionalidade.
Why it matters
This literature review concludes that biomarkers are fundamental tools for early diagnosis and prognosis of Alzheimer's disease, while spinal fluid and imaging tests remain the standard. It discusses peripheral biomarkers and probiotics only as they relate to biomarker modulation, and offers no treatment or cure.
-
Alzheimer's disease (AD) is a progressive brain disorder that leads to memory loss and a gradual decline in thinking and reasoning abilities.
Why it matters
This study used a support vector machine model to detect and classify Alzheimer's disease from MRI brain scans, reporting 98.16% classification accuracy and better accuracy, sensitivity and specificity than other machine learning models. It is a diagnostic classification tool only and does not test any treatment, cure or prevention.
-
31/100
An estimated two thirds of people living with Alzheimer’s disease or related dementias (ADRD) live and are cared for at home.
Why it matters
This study describes how common Alzheimer's disease and related dementias are in communities across five New England states, using Medicare data. It does not test any treatment, cure, or prevention, so it cannot say whether any approach works.
-
Eight proteins were differently expressed in carriers with larger WMH volumes (Figure 1).
Why it matters
In carriers of autosomal dominant Alzheimer's disease, higher CSF levels of matrix metalloproteinase-12 were found in those with severe cerebral microhemorrhages, suggesting MMP12 may be a marker for microhemorrhage risk. This is a biomarker association study and does not test a treatment or cure.
-
Alzheimer’s disease (AD) is an irreversible brain condition that impairs memory and cognitive processes.
Why it matters
This study proposed a machine learning model combining MRI and PET images to detect Alzheimer's disease, reporting improved accuracy compared to other methods. It is a detection method only and does not test any treatment, cure, or prevention.
-
Alzheimer disease (AD) is the most common cause of dementia and the sixth leading cause of death among adults ≥65 years in the United States (1).
Why it matters
This text notes that current Alzheimer's therapies are limited, with cholinesterase inhibitors offering modest cognitive benefit and newly approved anti-amyloid antibody infusions slowing mild-stage progression by about 30% while carrying risk of serious adverse effects. It states that most Alzheimer's drug trials have failed and a substantial unmet therapeutic need remains.
-
Of note, using large-scale transcriptome and chromatin profiling, we show that T cell shape microglia-specific metabolic plasticity in both genetic and epigenetic resolution.
Why it matters
Depletion of microglia, infiltrated T cells, or inhibition of IFN-γ signaling ameliorated brain atrophy in mouse models, revealing an immune hub involving activated microglia and T cell responses. These findings suggest potential therapeutic targets for preventing neurodegeneration in Alzheimer's disease and primary tauopathies.
-
Monoclonal antibodies such as lecanemab and donanemab show reduction in amyloid plaque and slowing of cognitive and functional decline (modest) in early AD (mild cognitive impairment or mild dementia).
Why it matters
Lecanemab and donanemab modestly slow cognitive and functional decline in early Alzheimer disease, while aducanumab showed mixed results and is not approved by Health Canada. Tau-targeting and anti-inflammatory agents are still under investigation and have not yet shown definitive benefit.
From across this topic
10 of the 5,172 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Late-onset Alzheimer's risk variants in memory decline, incident mild cognitive impairment, and Alzheimer's disease
- Cerebrovascular atherosclerosis correlates with Alzheimer pathology in neurodegenerative dementias
- Convolutional Neural Network Achieves 97.67 Percent Accuracy for Alzheimer MRI Classification
- Challenges in a Biological Definition of Alzheimer Disease
- Contribution of Alzheimer disease to mortality in the United States
- Cross-sectional and longitudinal association of sleep and Alzheimer biomarkers in cognitively unimpaired adults
- The mechanism of γ-Secretase dysfunction in familial Alzheimer disease
- Pathogenesis, diagnostics, and therapeutics for Alzheimer's disease: Breaking the memory barrier
- Genetic heterogeneity in Alzheimer disease and implications for treatment strategies
- Development of small molecules promoting tau degradation in Alzheimer disease